Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA) filed a Form 8-K on August 19, 2025, reporting the completion of the Single Ascending Dose (SAD) portion of its Phase 1 clinical trial for oral Ketamir-2. The company is an emerging growth company incorporated in Florida and trades on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) focused on clinical trial progress. The text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Clinical Progress
- Phase 1 SAD Completion: The SAD portion enrolled 32 participants across four cohorts with doses ranging from 50 mg to 600 mg.
- Safety Results: No severe or clinically significant adverse effects were observed at any dose level based on blinded safety data.
- Next Steps: The trial is advancing to the Multiple Ascending Dose (MAD) stage, evaluating daily doses of 150 mg, 300 mg, or 600 mg for five days in up to 24 participants.
- Regulatory Status: The company has received FDA IND clearance for neuropathic pain and plans to initiate a U.S. Phase 2a trial in Q4 2025, subject to ongoing results and regulatory review.
Guidance, Outlook, and Risks
Management expects to initiate the U.S. Phase 2a clinical trial in Q4 2025. The filing notes that this timeline is subject to ongoing results from the current Phase 1 trial and regulatory review. No specific financial guidance or discussion of material risks beyond standard clinical trial contingencies was provided in this text.
Investor Verification Checklist
- Confirm the enrollment and safety data for the upcoming Multiple Ascending Dose (MAD) stage.
- Verify the final regulatory approval and start date for the U.S. Phase 2a trial in Q4 2025.
- Review the company's cash runway and capital requirements to fund the Phase 2a trial, as no financial data was included in this filing.
- Monitor for any safety signals during the MAD portion that could impact the Phase 2a timeline.